Natera Inc
NASDAQ:NTRA
Natera Inc
Change in Working Capital
Natera Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Natera Inc
NASDAQ:NTRA
|
Change in Working Capital
$2.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-5%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Working Capital
-$2.8B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Working Capital
-$880m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Working Capital
-$514.8m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-22%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Working Capital
-$618.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Natera Inc
Glance View
In the dynamic world of biotechnology, Natera Inc. stands out as a leader in genetic testing and diagnostics. Founded with the vision of transforming how we understand our genetic blueprint, Natera has grown into a significant player, leveraging advanced molecular biology to decode human DNA with remarkable precision. The company's flagship technology, a proprietary cell-free DNA platform, underpins an array of genetic tests that cater to diverse needs in the fields of oncology, women's health, and organ health. Through this technology, Natera offers prenatal screening tests like Panorama, which can detect chromosomal abnormalities early in pregnancy, providing crucial insights for expectant parents. Additionally, the company's oncology solutions, such as Signatera, assist in tailoring personalized cancer treatment regimens by detecting minimal residual disease, thereby offering oncologists a powerful tool for disease management. Financially, Natera sustains its operations through a robust business model that combines direct billing and reimbursements from insurance providers, alongside partnerships with healthcare institutions. By offering innovative testing solutions, Natera generates revenue through test processing fees and related services. The company's growth is fueled by its investments in research and development, constantly pushing the boundaries to enhance test accuracy and expand into new markets. This strategic focus has not only broadened its portfolio but also fortified its ties with healthcare professionals and institutions worldwide. In navigating the complex landscape of genetic science, Natera continues to play a pivotal role in advancing personalized medicine, positioning itself as a linchpin in the future of healthcare diagnostics.
See Also
What is Natera Inc's Change in Working Capital?
Change in Working Capital
2.1m
USD
Based on the financial report for Dec 31, 2024, Natera Inc's Change in Working Capital amounts to 2.1m USD.
What is Natera Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
-5%
You don't have any saved screeners yet